Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Amortization of Deferred Charges (2016 - 2017)

Historic Amortization of Deferred Charges for Palisade Bio (PALI) over the last 5 years, with Q2 2017 value amounting to $12127.0.

  • Palisade Bio's Amortization of Deferred Charges fell 1556.78% to $12127.0 in Q2 2017 from the same period last year, while for Dec 2017 it was $59781.0, marking a year-over-year decrease of 8279.64%. This contributed to the annual value of $59781.0 for FY2017, which is 8279.64% down from last year.
  • As of Q2 2017, Palisade Bio's Amortization of Deferred Charges stood at $12127.0, which was down 1556.78% from $47654.0 recorded in Q1 2017.
  • Palisade Bio's 5-year Amortization of Deferred Charges high stood at $231381.0 for Q4 2013, and its period low was $12127.0 during Q2 2017.
  • For the 5-year period, Palisade Bio's Amortization of Deferred Charges averaged around $155644.9, with its median value being $207350.5 (2014).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first skyrocketed by 88150.9% in 2014, then tumbled by 9342.4% in 2016.
  • Quarter analysis of 5 years shows Palisade Bio's Amortization of Deferred Charges stood at $231381.0 in 2013, then dropped by 10.37% to $207388.0 in 2014, then grew by 3.88% to $215440.0 in 2015, then plummeted by 70.29% to $63998.0 in 2016, then plummeted by 81.05% to $12127.0 in 2017.
  • Its Amortization of Deferred Charges was $12127.0 in Q2 2017, compared to $47654.0 in Q1 2017 and $63998.0 in Q4 2016.